Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer
| Autor: | D. Azria, J. Doyen, M. Jarlier, I. Martel-Lafay, C. Hennequin, P. Etienne, V. Vendrely, E. François, G. de La Roche, O. Bouché, X. Mirabel, B. Denis, L. Mineur, J. Berdah, M. Mahé, Y. Bécouarn, O. Dupuis, G. Lledo, J. Seitz, L. Bedenne, S. Gourgou-Bourgade, B. Juzyna, T. Conroy, J. Gérard |
|---|---|
| Přispěvatelé: | UNICANCER - Institut régional du Cancer Montpellier Val d'Aurelle (ICM), CRLCC Val d'Aurelle - Paul Lamarque, Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Centre Léon Bérard [Lyon], Service de cancérologie et radiothérapie [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), CHU Bordeaux [Bordeaux], Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, Hôpital privé Jean Mermoz, Service d'hépato-gastroentérologie et cancérologie digestive (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), UNICANCER [Paris], Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Département d’Oncologie Médicale [Vandoeuvre Les Nancy], Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER-UNICANCER, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Lille-UNICANCER |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Adult Male medicine.medical_specialty Organoplatinum Compounds Colorectal cancer medicine.medical_treatment Rectum intermediate risk [SDV.CAN]Life Sciences [q-bio]/Cancer Adenocarcinoma Gastroenterology Disease-Free Survival chemoradiotherapy Capecitabine 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans rectal cancer Neoadjuvant therapy Aged Aged 80 and over business.industry Rectal Neoplasms neoadjuvant Hazard ratio Hematology Chemoradiotherapy Adjuvant Middle Aged medicine.disease Neoadjuvant Therapy 3. Good health Oxaliplatin Survival Rate Regimen 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Female business Chemoradiotherapy medicine.drug |
| Zdroj: | Annals of Oncology Annals of Oncology, Elsevier, 2017, 28 (10), pp.2436-2442. ⟨10.1093/annonc/mdx351⟩ Annals of Oncology, 2017, 28 (10), pp.2436-2442. ⟨10.1093/annonc/mdx351⟩ |
| ISSN: | 1569-8041 0923-7534 |
| DOI: | 10.1093/annonc/mdx351⟩ |
| Popis: | IF 11.855; International audience; BackgroundOutcome of intermediate risk rectal cancer may be improved by the addition of oxaliplatin during 5-fluoruracil concomitant neoadjuvant chemoradiotherapy. The purpose of this study is to analyze the main clinical results of the ACCORD12 trial (NCT00227747) in rectal cancer after 5 years of follow-up.Patients and methodsInclusion criteria were as follows: rectal adenocarcinoma accessible to digital examination staged T3-T4 Nx M0 (or T2 Nx distal anterior rectum). Two neoadjuvant chemoradiotherapy regimens were randomized: CAP45 (RT 45 Gy + capecitabine) and CAPOX50 (RT 50 Gy + capecitabine and oxaliplatin). Main end point was sterilization of the operative specimen. Acute and late toxicities were prospectively analyzed with dedicated questionnaires.ResultsBetween November 2005 and July 2008, 598 patients were included in the trial. After a median follow-up of 60.2 months, there was no difference between treatment arms in multivariate analysis either for disease-free survival or overall survival (OS) [P = 0.9, hazard ratio (HR)=1.02; 95% confidence interval (CI), 0.76–1.36 and P = 0.3, HR = 0.87; 95% CI, 0.66–1.15, respectively]. There was also no difference of local control in univariate analysis (P = 0.7, HR = 0.92; 95% CI, 0.51–1.66). Late toxicities were acceptable with 1.6% G3 anal incontinence, and |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|